You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Evaluating Photogenotoxicity using 3D Tissue Models

    SBC: MB RESEARCH LABORATORIES, INC.            Topic: NIEHS

    DESCRIPTION provided by applicant The objective of this proposal is to focus on evaluating materials for their ability to cause photogenotoxicity Photosensitivity is a harmful reaction that occurs when drugs or chemicals in the skin or eyes cause undesirable cellular damage when exposed to UV or visible light Photogenotoxicity is used as a means to screen a material for its photocarcinoge ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Enabling technologies for rapid and low cost molecular diagnosticshttps://apps.era.nih.gov/grantfolder/grantfolder/viewGrantFolder.do?businessAreaCode=GM&applID=8930749&folderID=90

    SBC: Atharva LLC (dba Atharva Sciences)            Topic: 172

    DESCRIPTION provided by applicant Molecular techniques including diagnostics that require separation or identification of different sized nucleic acid sequences have remained unchanged over the last several decades and rely primarily on some form of electrophoresis Diagnostics for several human diseases such as those associated with trinucleotide repeat instability exemplified by Fragile X s ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Developing a Point-of-Care Device for the Diagnosis of Sickle Cell Disease in Low Resource Settings

    SBC: ROCKLAND IMMUNOCHEMICALS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Hemoglobinopathies are the most common monogenic diseases with approximately of the worldandapos s population being carriers Sickle cell disease SCD and thalassemia are primarily hemoglobin disorders The current SCD diagnostic methods require expensive equipment and are performed by highly trained laboratory technologists Presently there are no simple ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. KL4 Surfactant to Mitigate Radiation-Induced Lung Injury

    SBC: DISCOVERY LABORATORIES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Exposure to ionizing radiation from a nuclear reactor accident or deliberate terrorist actions including the detonation of andquot dirty bombsandquot is a significant public health concern The lung is particularly susceptible to ionizing radiation injury from external sources or inhalation of radioactive particles from radioactive fall out Radiation pneumono ...

    SBIR Phase II 2014 Department of Health and Human Services
  5. A Novel Therapeutic for Invasive Candidiasis

    SBC: Fox Chase Chemical Diversity Center, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Systemic fungal infections are increasingly common especially in immune compromised patients While new antifungal drugs have been developed there is still a high mortality associated with these infections especially those due to Candida albicans other non albicans species NAS This is due to the limited spectrum of the drugs significant side effects as ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Small Molecule Inhibitor for EBV Latent Infection

    SBC: Vironika, LLC            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this research program is to develop a novel small molecule inhibitor of latent Epstein Barr Virus EBV infection EBV is a ubiquitous gamma herpesvirus that has been classified by the World Health Organization as a human carcinogen Vironika with its consortium partners the Wistar Institute and Fox Chase Chemical Diversity Center Inc will deve ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Modulators of LDL Metabolism

    SBC: Shifa Biomedical Corporation            Topic: NHLBI

    DESCRIPTION provided by applicant Heart disease is the leading cause of death for both men and women in the US accounting for nearly of all annual deaths A high cholesterol level is well known risk factors for heart disease Although blood cholesterol can be lowered using a number of marketed drugs of which statins are the leading drugs only of patients taking these drugs are achiev ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of High-expressing Ion Channels for Research and Therapeutic Applicat

    SBC: INTEGRAL MOLECULAR, INC            Topic: 300

    DESCRIPTION provided by applicant Ion channels such as Kv and Nav are involved in a number of human disorders including autoimmunity and pain that affect andgt million Americans annually and are poorly treated However ion channels are typically exceptionally difficult to express at high levels due to their structural complexity and toxicity s a result many research and therapeu ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of linkage-specific ubiquitin binding elements

    SBC: LIFESENSORS, INC.            Topic: 102

    DESCRIPTION provided by applicant Identification quantification and isolation of low abundance proteins from complex mixtures is at best a difficult task This is especially the case for proteins carrying a post translational modification PTM that affects their half life or regulatory properties Examples of such PTMs include phosphorylation glycosylation especially O GlcNAcylation an ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Polaris EECD: Improving Patient Engagement in Chemically Dependent Adults- Phase

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: NIDA

    DESCRIPTION provided by applicant Full engagement is essential for positive outcomes in addiction treatment Evidence based practices EBPs for enhancing treatment engagement include Motivational Interviewing Enhancement Therapy MI MET and andquot Matchingandquot patient services to patient needs Their adoption in routine clinical practice has been hindered by the inefficient methods avail ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government